The purpose of the study is to evaluate if postoperative antibiotic use in patients with mandible trauma reduce the risk of postoperative infections and does the benefit differ based on severity, soft tissue loss, other concomitant injuries, and medical problems
The purpose of this study is to evaluate the use of antibiotics postoperatively in non-infected mandible fractures compared to the lack of postoperative antibiotics in the same population. The first outcome measure is infection. Evidence of infection includes persistent swelling, fever, recurrent swelling, erythema, and purulent discharge. The second outcome measure is no infection. Absence of persistent swelling, fever, recurrent swelling, erythema, and purulent discharge. Outcome measures will be assessed on follow-up visits: post op week 1, post op week 3, and post op week 6-8. Latest follow-up is up to 8 weeks. If the subject presents with any of the above mentioned symptoms during the 8 week post-op period, the subject will be considered positive for infection. Prospective randomized trial: Control group will not receive any postoperative antibiotics other than what is accepted as preoperative prophylactic antibiotics as per current standards of care. Trial groups will receive a single post-operative dose administration of Unasyn 3g or Clindamycin 600mg (for penicillin allergies), then the patients in the trial group will be switched to oral Augmentin 875mg twice a day for 7 days (Amoxicillin and Clavulanic acid which is clinically interchangeable with Unasyn), or oral Clindamycin 150mg to 300mg four times a day for 7 days (for penicillin allergies). If the patient is discharged home prior to completing 7 days of oral antibiotic therapy, patient will receive prescription to finish the remaining doses of antibiotics for a total period of 7 days. The patient will follow up post op week 1, post op week 3, and post op week 6-8. Latest follow-up is up to 8 weeks. Patients will be monitored for any complications, including reaction to IV and oral antibiotics. Patient will assessed after the one-time post-op IV antibiotic dose and during their follow-up visits at weeks 1, 3, and 6-8.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
13
Trial groups will receive a single post-operative dose administration of Unasyn 3g or Clindamycin 600mg (for penicillin allergies)
the patients in the trial group will be switched to oral Augmentin 875mg twice a day for 7 days, or oral Clindamycin 150mg to 300mg four times a day for 7 days (for penicillin allergies).
Control group will not receive any postoperative antibiotics other than what is accepted as preoperative prophylactic antibiotics as per current standards of care
Memorial Hermann Hospital
Houston, Texas, United States
Th University of Texas Health Science Center at Houston
Houston, Texas, United States
Evidence of infection as measured by presence of persistent swelling,
Time frame: post treatment week1
Evidence of infection as measured by presence of persistent swelling,
Time frame: post treatment week 3
Evidence of infection as measured by presence of persistent swelling,
Time frame: post treatment week 6-8
Evidence of infection as measured by presence of fever
Time frame: post treatment week 1
Evidence of infection as measured by presence of fever
Time frame: post treatment week 3
Evidence of infection as measured by presence of fever
Time frame: post treatment week 6-8
Evidence of infection as measured by presence of recurrent swelling
Time frame: post treatment week 1
Evidence of infection as measured by presence of recurrent swelling
Time frame: post treatment week 3
Evidence of infection as measured by presence of recurrent swelling
Time frame: post treatment week 6-8
Evidence of infection as measured by presence of erythema
Time frame: post treatment week 1
Evidence of infection as measured by presence of erythema
Time frame: post treatment week 3
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Evidence of infection as measured by presence of erythema
Time frame: post treatment week 6-8
Evidence of infection as measured by presence of purulent discharge
Time frame: post treatment week 1
Evidence of infection as measured by presence of purulent discharge
Time frame: post treatment week 3
Evidence of infection as measured by presence of purulent discharge
Time frame: post treatment week 6-8
No evidence of infection as measured by absence of persistent swelling
Time frame: post treatment week 1
No evidence of infection as measured by absence of persistent swelling
Time frame: post treatment week 3
No evidence of infection as measured by absence of persistent swelling
Time frame: post treatment week 6-8
No evidence of infection as measured by absence of fever
Time frame: post treatment week 1
No evidence of infection as measured by absence of fever
Time frame: post treatment week 3
No evidence of infection as measured by absence of fever
Time frame: post treatment week 6-8
No evidence of infection as measured by absence of recurrent swelling
Time frame: post treatment week 1
No evidence of infection as measured by absence of recurrent swelling
Time frame: post treatment week 3
No evidence of infection as measured by absence of recurrent swelling
Time frame: post treatment week 6-8
No evidence of infection as measured by absence of erythema
Time frame: post treatment week 1
No evidence of infection as measured by absence of erythema
Time frame: post treatment week 3
No evidence of infection as measured by absence of erythema
Time frame: post treatment week 6-8
No evidence of infection as measured by absence of purulent discharge
Time frame: post treatment week 1
No evidence of infection as measured by absence of purulent discharge
Time frame: post treatment week 3
No evidence of infection as measured by absence of purulent discharge
Time frame: post treatment week 6-8